USD 0.1
(0.0%)
Year | Eps | Eps Growth |
---|---|---|
2023 | 0.00 USD | -17.02% |
2022 | 0.00 USD | -2.08% |
2021 | 0.00 USD | 14.29% |
2020 | 0.00 USD | 7.69% |
2019 | 0.00 USD | 8.33% |
2018 | 0.00 USD | -5.26% |
2017 | 0.00 USD | 5.56% |
2016 | 0.00 USD | 16.13% |
2015 | 0.00 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | 0.00 USD | -15.38% |
2024 Q3 | 0.00 USD | -27.27% |
2024 Q1 | 0.00 USD | 30.0% |
2023 Q4 | 0.00 USD | 25.0% |
2023 FY | - USD | -17.02% |
2023 Q1 | 0.00 USD | 0.0% |
2023 Q2 | 0.00 USD | -16.67% |
2023 Q3 | 0.00 USD | -20.0% |
2022 Q2 | 0.00 USD | 0.0% |
2022 FY | - USD | -2.08% |
2022 Q4 | 0.00 USD | 0.0% |
2022 Q3 | 0.00 USD | 0.0% |
2022 Q1 | 0.00 USD | -7.69% |
2021 Q1 | 0.00 USD | 0.0% |
2021 FY | - USD | 14.29% |
2021 Q4 | 0.00 USD | 8.33% |
2021 Q3 | 0.00 USD | 9.09% |
2021 Q2 | 0.00 USD | 0.0% |
2020 FY | - USD | 7.69% |
2019 FY | - USD | 8.33% |
2018 FY | - USD | -5.26% |
2017 FY | - USD | 5.56% |
2016 FY | - USD | 16.13% |
2015 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
AstraZeneca PLC | 3.84 USD | 99.898% |
Bristol-Myers Squibb Company PFD CONV 2 | 3.88 USD | 99.899% |
CSPC Pharmaceutical Group Limited | 0.07 USD | 94.429% |
Clarus Therapeutics Holdings, Inc. | -8.04 USD | 100.049% |
Novartis AG | 7.63 USD | 99.949% |